



Genprex to Present at the 11th Annual LD Micro Main Event

December 3, 2018

Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney Varner, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Genprex is scheduled to present on Wed., Dec. 5, 2018, at 10:30 a.m. PST. Genprex management will also attend one-on-one meetings with institutional investors throughout the day.

The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 250 companies presenting to an audience of over 1,200 attendees.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex's initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company's web site at <http://www.genprex.com> or follow Genprex on Twitter at <https://twitter.com/genprex> and Facebook at <https://www.facebook.com/genprexinc/>.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMI) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit <http://www.ldmicro.com> for more information.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181203005478/en/>

Source: Genprex, Inc.

Media:

James Heins
ICR Healthcare
203-682-8251
James.Heins@icrinc.com

Investors:

Stephanie Carrington
ICR Healthcare
646-277-1282
Stephanie.Carrington@icrinc.com